Hinge Health (HNGE) opened Q1 2026 with revenue of $182.3 million and basic EPS of $0.43, providing a clear view of how the business is currently converting its top line into per share results. Over the past year, the company has reported quarterly revenue of $117.3 million in Q4 2024, $123.8 million in Q1 2025, $139.1 million in Q2 2025, $154.2 million in Q3 2025, $170.7 million in Q4 2025 and now $182.3 million in Q1 2026. Basic EPS over the same period has ranged from $1.98 to $7.38, followed by a mix of losses and smaller profits as net income reset. For investors, this set of results draws attention to how efficiently Hinge Health is turning that larger revenue base into more stable, sustainable margins.

See our full analysis for Hinge Health.

With the headline numbers established, the next step is to examine how this earnings release aligns with the widely followed narratives around Hinge Health's growth potential, risk profile and path to more consistent profitability.

49.8% revenue growth meets volatile profits

• On a trailing 12 month basis, Hinge Health generated US$646.3 million of revenue, up from US$390.4 million a year earlier, while moving from a US$11.9 million loss to a much larger US$511.4 million loss over the same comparison.
• What stands out for the bullish narrative is the mix of strong top line growth and swings in profitability, because bulls point to 49.8% revenue growth and forecasts for 16.8% annual revenue growth and 78.2% annual earnings growth, yet the trailing 12 month loss of US$511.4 million still needs to be bridged to those targets.
  • Bulls highlight that Q1 2026 net income of US$34.0 million compares with a trailing 12 month loss of US$511.4 million, which suggests recent quarters look very different to the full year picture.
  • The same data set expects Hinge Health to become profitable within three years, so investors can compare that path with the pattern of quarterly results from US$121.3 million profit in Q1 2025 through the US$575.7 million loss in Q2 2025 to the more recent Q4 2025 and Q1 2026 profits.

Bulls argue that this swingy profit history could still line up with a long term improvement story once you stack Q1 2026 against those forecasts, but it puts more weight on whether future quarters keep looking like the recent ones or revert toward the trailing 12 month loss profile. 🐂 Hinge Health Bull Case

Premium 6.6x P/S against healthcare peers

• The stock trades on a P/S of 6.6x while peers sit at 4.3x and the broader US Healthcare group at 1.2x, so the market is currently paying a higher multiple for each dollar of Hinge Health revenue than for many other healthcare stocks.
• Bears focus on this valuation gap because it sits alongside current unprofitability, with a trailing 12 month net margin that is negative and a loss of US$511.4 million, which they argue leaves little room for disappointment if revenue growth or margin improvement slows.
  • Critics highlight that even though Q1 2026 produced US$34.0 million of net income and Q4 2025 produced US$32.1 million, the trailing 12 month figures still show a large loss, so the premium P/S is not yet backed by consistent profits.
  • The same risk set points out that revenue is forecast to grow around 16.8% per year, which is higher than a US market reference of 11.3%, but not so extreme that it automatically justifies a much higher multiple if margins remain negative over a full year.

Skeptics suggest that if profitability drifts away from the recent profitable quarters toward the trailing loss profile, this richer P/S could come under pressure, so they watch each new report for signs that the negative net margin is shrinking in a durable way. 🐻 Hinge Health Bear Case

DCF fair value far above US$54.84

• The provided DCF fair value of US$183.69 sits well above the current share price of US$54.84, even though the company is currently loss making on a trailing 12 month basis.
• Consensus narrative supporters point to this DCF fair value gap together with analyst projections, which assume revenue rising to US$960.4 million and earnings of US$85.8 million with an 8.9% margin, while critics of that view flag the need to move from a US$511.4 million trailing 12 month loss and a negative margin to those targets.
  • Consensus assumptions require the stock to trade at a P/E of 88.4x on the projected US$85.8 million of earnings, which is much higher than the current P/S of 6.6x converted into any implied P/E because there are no trailing earnings today.
  • What matters for you as an investor is whether the recent quarterly profits of US$27.1 million in Q4 2024, US$121.3 million in Q1 2025, US$32.1 million in Q4 2025 and US$34.0 million in Q1 2026 look more like the future than the US$575.7 million loss recorded in Q2 2025 that still weighs on the trailing 12 month numbers.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Hinge Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the combination of optimism and concern in this earnings story feels conflicting, treat that as a prompt to move quickly, review the numbers yourself, and then compare them with the 3 key rewards.

See What Else Is Out There

Hinge Health combines a premium valuation with a trailing 12 month loss of US$511.4 million and uneven profitability, which leaves little room for earnings disappointments.

If that mix of rich pricing and volatile profits makes you cautious, you may wish to compare it with companies screened for stronger value support and clearer earnings backing through the 45 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.